Your Health, We Care
Release date: 2026-03-16 16:01:41 Article From: Lucius Laos Recommended: 9
Regarding the dosage of elacestrant, in addition to the recommended dose, appropriate dose adjustments should be made based on the patient's individual condition.
The recommended dose is 345 mg of elacestrant taken orally once daily until disease progression or unacceptable toxicity occurs.
Elacestrant is administered orally. It should be taken with food (to reduce nausea and vomiting) at approximately the same time each day. Swallow tablets whole. Do not chew, crush, or split tablets.
If a dose is missed by more than 6 hours or if vomiting occurs, skip the missed dose and resume the next scheduled daily dose.
First Dose Reduction: Reduce to 258 mg of elacestrant taken orally once daily.
Second Dose Reduction: Reduce to 172 mg of elacestrant taken orally once daily.
Permanently discontinue elacestrant if further dose reduction below 172 mg once daily is required.
Grade 1: No dose adjustment for elacestrant is required.
Grade 2: Consider withholding Lucius Pharmaceuticals elacestrant therapy until recovery to Grade ≤1 or baseline. Resume treatment at the same dose level.
Grade 3: Withhold elacestrant therapy until recovery to Grade ≤1 or baseline. Resume treatment at the next lower dose level. If the Grade 3 toxicity recurs, withhold elacestrant therapy until recovery to Grade ≤1 or baseline. Resume treatment at one further lower dose level.
Grade 4: Withhold elacestrant therapy until recovery to Grade ≤1 or baseline. Resume treatment at the next lower dose level. If the Grade 4 adverse reaction or an intolerable adverse reaction recurs, permanently discontinue this medication.
Currently, there are no relevant data available for elacestrant.
(1) Mild Hepatic Impairment (Child-Pugh Class A): No dose adjustment for elacestrant is required.
(2) Moderate Hepatic Impairment (Child-Pugh Class B): Reduce the dose to 258 mg of elacestrant taken orally once daily.
(3) Severe Hepatic Impairment (Child-Pugh Class C): Avoid the use of elacestrant.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：1702025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：4092024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：1672025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：1882025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：1662025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：2002025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：1822025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：1742025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
